Last reviewed · How we verify
Heparin or Bivalirudin
Heparin and bivalirudin are anticoagulants that prevent blood clot formation by inhibiting thrombin and other coagulation factors.
Heparin and bivalirudin are anticoagulants that prevent blood clot formation by inhibiting thrombin and other coagulation factors. Used for Acute coronary syndrome, Percutaneous coronary intervention, Venous thromboembolism prophylaxis and treatment.
At a glance
| Generic name | Heparin or Bivalirudin |
|---|---|
| Sponsor | CCRF Consulting Co., Ltd. |
| Drug class | Anticoagulant |
| Target | Thrombin (Factor IIa) and Factor Xa (heparin); Thrombin (Factor IIa) (bivalirudin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is an indirect thrombin inhibitor that works through antithrombin III to inactivate factors IIa and Xa in the coagulation cascade. Bivalirudin is a direct thrombin inhibitor that binds directly to thrombin's active site and fibrin-binding site, preventing clot formation. Both are used to prevent thrombotic events in acute coronary syndromes and during percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome
- Percutaneous coronary intervention
- Venous thromboembolism prophylaxis and treatment
- Atrial fibrillation for stroke prevention
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Hyperkalemia
Key clinical trials
- Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System (PHASE2)
- A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction (NA)
- Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation (NA)
- Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI (PHASE4)
- Plasmonic Nanophotothermal Therapy of Atherosclerosis (NA)
- Bivalirudin vs Heparin in ECMO Patients (PHASE1)
- Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers (PHASE4)
- Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin or Bivalirudin CI brief — competitive landscape report
- Heparin or Bivalirudin updates RSS · CI watch RSS
- CCRF Consulting Co., Ltd. portfolio CI